-- There was a less than 5% discontinuation rate due to adverse events.
-- During a 6-month follow-up period, there were no new safety observations
compared to those seen during acute treatment.
NeuroStar TMS Therapy is contraindicated in patients with implanted metallic devices or non-removable metallic objects in or around the head. As with any antidepressant treatment, patients should be monitored for symptoms of worsening depression. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment. Efficacy has not been established in patients who have failed to receive benefit from two or more prior antidepressant treatments at minimal effective dose and duration in the current episode.
"Depression is a debilitating illness, and existing treatment options are frequently ineffective or intolerable due to side effects," said Neuronetics' President and CEO, Bruce Shook. "The availability of NeuroStar TMS Therapy means that patients suffering from this disease now have an entirely new non-systemic and non-invasive treatment option that has been proven safe and effective."
Availability of NeuroStar TMS Therapy
Initially, NeuroStar TMS Therapy will only be available in a limited number of treatment centers around the country. For specific information on treatment locations with NeuroStar TMS Therapy, please visit http://www.NeuroStarTMS.com or call the Neuronetics Customer Service Center at (877) 600-7555.
Depression affects at least 14 million American adults each year.
Researchers estimate that by the year 2020, depression will be the second
leading cause of disability worldwide. Each year, over 30,000 people in the
U.S. commit suicide, 60% of which suffer from depression. The economic
burden of depression in 2000 was estimated at $83.1 billion
|SOURCE Neuronetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved